AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02328729 — intervention group
Intervention type: PROCEDURE
Intervention: Mandibular block without Epinephrine
Description: Delivery of mandibular block anesthesia for dental treatment with Mepivacaine 3% without Epineprine
Study NCT02328729 — intervention group
Intervention type: PROCEDURE
Intervention: C-CLAD-IL without Epinephrine
Description: Delivery of C-CLAD-ILanesthesia for dental treatment with Mepivacaine 3% without Epineprine
Study NCT02328729 — intervention group
Intervention type: PROCEDURE
Intervention: nfiltration without Epinephrine
Description: Delivery of infiltration anesthesia for dental treatment with Mepivacaine 3% without Epineprine
Study NCT01800760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotics once a day for three weeks.
Study NCT03693898 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observeational
Description: No intervention, observational
Study NCT04127929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restoration of cavities using glass carbomer material (GCP Dental)
Description: Detection of caries then restoration of cavities
Study NCT04127929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restoration of cavities using nanocomposite resin (Tokuyama Estelite Posterior)
Description: Detection of caries then restoration of cavities
Study NCT02004171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic cigarette
Description: V2 Cigs with 24 mg nicotine cartridges
Study NCT02004171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine inhaler
Description: nicotine inhaler with 10 mg nicotine cartridges
Study NCT03017664 — intervention group
Intervention type: OTHER
Intervention: Peptide-based enteral formula
Description: Peptide-based, higher protein and higher calorie enteral formula
Study NCT03017664 — intervention group
Intervention type: OTHER
Intervention: Retrospective review of enteral tube feeding formula
Description: Enteral formula tube feeding will be retrospectively reviewed
Study NCT02569983 — intervention group
Intervention type: OTHER
Intervention: Observational cohort
Description: No intervention - observational study
Study NCT01779362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Titrated to 1000 mg BID
Study NCT01779362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Titrated to 1.8 mg/day
Study NCT01779362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Titrated to target fasting glucose \<90 mg/dl
Study NCT01779362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching to metformin 1000 mg BI
Study NCT02353663 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Echocardiography examination
Study NCT01718691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-0501
Description: A dose of 90 mg/m\^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
Study NCT01718691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: A dose of 375 mg/m\^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
Study NCT02502500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study NCT02502500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Study NCT02502500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Study NCT00673829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Modified T Cells
Description: Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
Study NCT00673829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Modified T Cells and Interleukin 2
Description: One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
Study NCT03512886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-task training
Description: In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
Study NCT03512886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single task training
Description: An exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
Study NCT03974958 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Tissue-library
Description: circulating biomarkers (miRNA panel) analysis of blood samples
Study NCT03380572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senhance Assisted Cholecystectomy
Description: Cholecystectomy performed using Senhance surgical robotic system
Study NCT03380572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Cholecystectomy
Description: Standard laparoscopic cholecystectomy
Study NCT00354211 — intervention group
Intervention type: DEVICE
Intervention: minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)
Study NCT02210195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: 125 mg daily for 8 weeks.
Study NCT02210195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 8 weeks.
Study NCT02210195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
Study NCT02210195 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
Study NCT01184807 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: OPB-51602
Description: OPB-51602 at a dose of 2, 5, 10, 20, 40, 60, 80, or 100 mg/day,will be orally administered to subjects once daily for 2 weeks in each cycle of treatment in Dose Escalation Stage.A 2-day treatment-free interval will occur on Days 2 and 3 for PK sampling. Study drug administration will resume on Day 4 and continue until Day 17 in cycle 1.In Expansion stage part 1, OPB-51602 will be administered at recommend dose (4mg) for 3 weeks per cycle 9 2 weeks treatment and 1 week washout). There is also 2-day treatment free interval between Day 1 and Day 4 for PK sampling in cycle 1.In Expansion stage part 2, subject dosing will be started on Day 1 without 2-day treatment free interval and continued until Day 28 at recommend dose (4mg) first in Cycle 1. The same subjects will be treated at MTD(5mg)from cycle 2 onwards for 4 weeks per cycle.
Study NCT04337073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
Study NCT04337073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
Study NCT01200355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
Study NCT01200355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: posaconazole
Description: Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
Study NCT02331407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic arm therapy
Description: Training with the ReoGo device
Study NCT04623151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online leaflet about foot care
Description: Short text-based leaflet about foot care, presented online
Study NCT04623151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online leaflet about foot care
Description: Short text-based leaflet about foot care, presented online
Study NCT03940534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAD
Description: TAD is a device used to aid medication adherence.
Study NCT00432120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
Study NCT03586193 — intervention group
Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy
Description: pars plana vitrectomy without ICG staining and ILM peeling
Study NCT04208711 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: biological sample
Description: whole blood sample
Study NCT02004795 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BNCT + IG-IMRT
Description: Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)
Study NCT03805048 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention
Description: PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.
Study NCT03357055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV infusion of 0.25mg/kg of ketamine over 10 minutes before pneumatic tourniquet inflation. Throughout procedure patient will receive 0.25mg/kg of ketamine infusion.
Study NCT03357055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation
Study NCT03234452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoflorene plus
Description: 2 vials with dosing cap (10 mL) a day per os
Study NCT03234452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lactoflorene plus
Description: 2 vials with dosing cap (10 mL) a day per os
Study NCT02940379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02940379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Pharmaceutical form: HCl syrup~Route of administration: oral
Study NCT02940379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02499315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 357
Description: Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
Study NCT02499315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
Study NCT03474744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Solution for IV infusion
Study NCT03474744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Solution for IV infusion
Study NCT01922011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: IV daptomycin Infusion A in 12 to \<18 years old (7 mg/kg); in 7 to \< 12 year olds (9 mg/kg); in 24 months to \<7 year olds (12 mg/kg); in 12 to \<24 month olds (12 mg/kg). Infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
Study NCT01922011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin (or equivalent)
Description: IV vancomycin (or equivalent) (Infusions A,B,C,D), 10 to 15 mg/kg, infused over 60 (± 10) minutes q6h (± 1 hour)
Study NCT01922011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nafcillin (or equivalent)
Description: IV nafcillin (or β-lactam equivalent) (Infusions A,B,C,D) at 100-200 mg/kg/day, in divided doses infused over 60 (± 10) min q6h (± 1 hour)
Study NCT05141994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5mg of BAT5906
Description: Specification: 2.5mg of BAT5906
Study NCT05141994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of BAT5906
Description: Specification: 4mg of BAT5906
Study NCT02664883 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Correlative studies
Study NCT02664883 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and urine samples
Study NCT02664883 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02664883 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Correlative studies
Study NCT00357162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV
Study NCT04180930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-5
Description: Clinician Administered PTSD Scale for DMS-5
Study NCT04180930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PSSI-5
Description: PTSD Symptom Scale Interview for DSM-5
Study NCT04180930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-IV
Description: Clinician Administered PTSD Scale for DSM-IV
Study NCT01859741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-59R5
Description: OMP-59R5 administered intravenously
Study NCT01859741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: administered intravenously
Study NCT01859741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: administered IV
Study NCT01859741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: administered intravenously
Study NCT02447029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal 2% Xylocaine
Description: patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
Study NCT02447029 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: standard lidocaine paracervical block
Description: 1% lidocaine paracervical injection
Study NCT02011334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg will be administered once weekly by subcutaneous injection.
Study NCT01053936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (amorphous dispersion)
Description: Oral, once daily
Study NCT00315822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 80% oxygen
Description: Supplemental oxygen will be administered during surgery
Study NCT00315822 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 30% oxygen
Description: Subjects undergoing surgery will receive routine administration of oxygen
Study NCT01601795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: volatile Anaesthetic, duration during cardiopulmonary bypass
Study NCT01601795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: volatile anesthetic, duration during cardiopulmonary bypass time
Study NCT04447365 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: device interrogation
Description: All patients will have a pre-existing ICD and a diagnosis of cardiomyopathy with left ventricular systolic function of 35% or less by echocardiogram done within 3 years of the time of enrollment.
Study NCT01257542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
Study NCT01257542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single 10 mL dose of matching placebo syrup
Study NCT03147287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is a drug that may stop cancer cells from growing
Study NCT03147287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
Study NCT03147287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
Study NCT03147287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
Study NCT01058824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lincomycin
Description: Single Dose Hard Gelatin Capsule - oral - 500 mg
Study NCT01058824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lincomycin
Description: Single Dose Hard Gelatin Capsule - oral - 500 mg
Study NCT00790933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion
Study NCT01567800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Description: PET scan with the radiolabelled tracer 18F-FAZA
Study NCT00792480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle counseling
Description: The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.~At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise.
Study NCT03837834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation Leg Cycling Exercise
Description: FES- leg cycling for 45 minutes (3 min warm up + 40 min HIIT + 2 min cooldown). The FES will be applied via surface electrodes and the stimulation intensity based on your tolerance level.
Study NCT03651219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib Mmesylate tablets 250mg/d, po, there's totally 4-6 cycles(21days per cycle)
Study NCT03651219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 80mg/m2 d1, d8, vi, there's totally 4-6 cycles(21days per cycle)
Study NCT01295892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: transdermal 17-β-estradiol 1mg/day during three months
Study NCT01295892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estrogen
Description: transdermal 17-β-estradiol 1mg/day during three months
Study NCT03611127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: pulmonary rehabilitation standardized program
Study NCT02265744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699